Integumentary System Diseases
The integumentary system, comprising the skin, hair, nails, and associated glands, serves as a vital barrier between the body and the external environment. However, this complex system is vulnerable to various autoimmune and inflammatory diseases. Our company provides drug and therapy development services to address integumentary system autoimmune and inflammatory diseases.
Introduction to Integumentary System Autoimmune Diseases
Integumentary system autoimmune and inflammatory diseases encompass a range of conditions characterized by abnormal immune responses and inflammation targeting the skin and its associated structures. These diseases can manifest in different forms, including but not limited to psoriasis, atopic dermatitis, pemphigus, and lupus erythematosus. They often result from a dysregulated immune system that mistakenly recognizes self-components as foreign or triggers an exaggerated immune response against harmless substances.
Immunology in Integumentary System Autoimmune Diseases
Immune cell activation and migration: T cells, B cells, and dendritic cells contribute to the pathogenesis of these diseases. Targeting their activation, proliferation, or migration pathways can help alleviate disease symptoms. For example, inhibitors of Janus kinase (JAK) enzymes have shown efficacy in psoriasis and atopic dermatitis by blocking cytokine signaling.
Immune checkpoints: Immune checkpoint molecules, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), regulate immune responses. Modulating these checkpoints with antibodies can restore immune balance and reduce disease severity.
Fig.1 Schematic illustration of a potential tertiary lymphoid structure (TLS) in skin autoimmunity. (Fetter T., et al., 2020)
Value of Therapy Development for Integumentary System Autoimmune Diseases
The prevalence of autoimmune diseases affecting the integumentary system has been on the rise, impacting a significant number of individuals today. Various factors such as time, age, gender, season, and comorbidities contribute to the increased prevalence of these diseases. The development of drugs targeting autoimmune diseases of the integumentary system holds great promise in improving outcomes. Numerous pharmaceutical companies have made substantial investments in the research and development of drugs to effectively treat these conditions. Their aim is to alleviate symptoms, control disease progression, and reduce the occurrence of complications. The following table presents the investigational status of some drugs being developed for the treatment of autoimmune diseases affecting the integumentary system.
| Condition (Integumentary System Autoimmune Diseases) | Drug Name | Organization | Status |
|---|---|---|---|
| Bullous Pemphigoid | NPB-01 | Nihon Pharmaceutical | Launched - 2015 |
| Behçet's Disease | apremilast | Amgen | Launched - 2019 |
| Alopecia Areata | abatacept | Bristol-Myers Squibb | Phase II |
| Psoriasis | ponesimod | Actelion | Phase II |
| Dermatomyositis | adrenocorticotropic hormone | Mallinckrodt | Sale |
| Psoriasis | infliximab | Merck & Co | Sale |
Our Services
Our esteemed company provides a wide range of services dedicated to diagnostic and therapy development for autoimmune and inflammatory diseases affecting the integumentary system. With a strong emphasis on cutting-edge research, we collaborate with esteemed scientists to identify and validate potential therapeutic targets.
Our preclinical research services involve conducting in vitro experiments and animal model development to evaluate the effectiveness and safety of potential therapeutic candidates. We employ state-of-the-art techniques and technologies to assess drug pharmacokinetics, pharmacodynamics, and immunomodulatory effects. This rigorous preclinical testing ensures the optimal selection and development of therapeutic candidates for subsequent trials.
Types of Integumentary System Autoimmune Diseases
If you are interested in our services, please don't hesitate to contact us.
Reference
- Fetter T., et al. "Skin-associated B cells in the pathogenesis of cutaneous autoimmune diseases—implications for therapeutic approaches." Cells 9.12 (2020): 2627.